![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/24/2887749/0/en/Adlai-Nortye-Ltd-to-Present-Encouraging-Data-of-the-Combination-of-AN0025-and-Definitive-Chemoradiotherapy-dCRT-at-ASCO-2024.html
https://www.globenewswire.com/news-release/2024/05/22/2886439/0/en/Adlai-Nortye-Announces-First-Patient-Dosed-in-Randomized-Phase-II-Clinical-Trial-of-Palupiprant-AN0025-for-the-Treatment-of-Locally-Advanced-Rectal-Cancer-with-Radiation-Therapy.html
https://www.globenewswire.com/news-release/2024/03/29/2854696/0/en/Adlai-Nortye-Announces-Appointment-of-Dr-Archie-Tse-as-the-Head-of-Research-Development.html
https://www.globenewswire.com//news-release/2023/11/17/2782524/0/en/Adlai-Nortye-Announces-Completion-of-Patient-Enrollment-in-Global-Phase-III-Clinical-Trial-of-Buparlisib-AN2025-in-Combination-with-Paclitaxel-for-the-Treatment-of-Recurrent-or-Met.html
https://www.globenewswire.com//news-release/2023/10/23/2764705/0/en/Adlai-Nortye-Ltd-Nucleai-awarded-ESMO-2023-BEST-Poster-Award.html
https://www.globenewswire.com//news-release/2023/10/03/2753988/0/en/Adlai-Nortye-Ltd-Announces-Closing-of-Initial-Public-Offering.html
https://www.globenewswire.com//news-release/2023/09/29/2751764/0/en/Adlai-Nortye-Ltd-Announces-Pricing-of-Initial-Public-Offering.html
https://www.prnewswire.com/news-releases/oncolytics-biotech-partner-adlai-nortye-advances-chinese-bridging-trial-of-pelareorep-paclitaxel-combination-treatment-in-breast-cancer-to-final-dosing-cohort-301509468.html
https://www.prnewswire.com/news-releases/adlai-nortye-announces-appointment-of-dr-victoria-demby-as-senior-vice-president-of-global-regulatory-affairs-301502011.html
https://www.prnewswire.com/news-releases/adlai-nortye-announces-publication-of-preclinical-research-of-an3025-anti-htnfr2in-frontiers-in-immunology-301486211.html